Browse > Article
http://dx.doi.org/10.15432/JKTO.2021.26.1.039

A Case Report of Pancreatic Cancer with Liver Metastasis Patient Treated with Integrative Cancer Treatment  

Ko, Eun-ju (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Myong, Ji-soo (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Kim, Jong-hee (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Park, Ji-hye (East West Cancer Center, Seoul Korean Medicine Hospital of Daejeon University)
Park, So-jung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Lee, Yeon-weol (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Yoo, Hwa-seung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Publication Information
Journal of Korean Traditional Oncology / v.26, no.1, 2021 , pp. 39-48 More about this Journal
Abstract
Objective: The purpose of this study is to report effects and potential of Integrative Cancer Treatment (ICT) on metastatic pancreatic cancer patient. Methods: A 79-year-old pancreatic cancer patient diagnosed with metastasis on liver visited the Daejeon Korean medicine hospital of Daejeon university East West Cancer Center (EWCC) on May 2021. The patient has been received chemotherapy (gemcitabine plus abraxane) and concurrently treated with ICT since May 2021. The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA19-9) and numeric rating scales (NRS). Laboratory analysis and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0 were used to evaluate the safety of ICT. Results: After treatment, constipation was relieved from NRS 5-6 to 2, both leg numbness was improved from NRS 9 to 2. Tumor size was generally decreased accompanying by reducing the levels of tumor markers. There were no severe adverse events induced by ICT based on NCI CTCAE version 5.0. Conclusion: This case study suggests that ICT in combination with chemotherapy may help in the treatment of patients with metastatic pancreatic cancer.
Keywords
Pancreatic cancer; Liver metastasis; Gemcitabine; Abraxane; Integrative Cancer Treatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA: a cancer journal for clinicians 70:7-30, 2020.   DOI
2 Roe, J. S. et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 170:875-888 e820, 2017.   DOI
3 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 395:2008-2020, 2020.   DOI
4 Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Buchler MW, et al. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Pancreatol. 3:1-11, 2020.   DOI
5 Siegel, R.L. et al. Cancer statistics, 2017. CA Cancer J. Clin. 67:7-30, 2017.   DOI
6 Park BK, Yoo HS, Lee YW, Han SS, Cho JH, Son CG, Cho CK. Retrospective cohort analysis for lung cancer patients treated with Wheel Balance Therapy (WBT). Korean J Orient Int Med. 19(2):45-56, 2009.
7 National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/.
8 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
9 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 71(1):7-33, 2021.   DOI
10 Walter, F. M. et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): A prospective cohort study. Lancet Gastroenterol. Hepatol. 1, 298-306, 2016.   DOI
11 Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 371:1039-1049, 2014.   DOI
12 Sriramulu Elluru, Jean-Paul Duong Van Huyen, Sandrine Delignat, Fabienne Prost, Jagadeesh Bayry, Michel D. Kazatchkine, Srini V. Kaveri, Arzneimittelforschung. 56(6):461-466, 2006   DOI
13 D.V. Catenacci, M.R. Junttila, T. Karrison, N. Bahary, M.N. Horiba, S.R. Nattam, R. Marsh, J. Wallace, M. Kozloff, L. Rajdev, D. Cohen, J. Wade, B. Sleckman, H. J. Lenz, P. Stiff, P. Kumar, P. Xu, L. Henderson, N. Takebe, R. Salgia, X. Wang, W. M. Stadler, F.J. de Sauvage, H.L. Kindler, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J. Clin. Oncol. 33:4284-4292, 2015.   DOI
14 Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancre-atic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 18:688, 2018.   DOI
15 Y. Miyasaka, T. Ohtsuka, R. Kimura, R. Matsuda, Y. Mori, K. Nakata, D. Kakihara, N. Fujimori, T. Ohno, Y. Oda, M. Nakamura, Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery, Annals of Surgical Oncology. Springer New York LLC March. 1528-1534, 2019.
16 E. Giacomini, M. Severa, M. Cruciani, M.P. Etna, F. Rizzo, M. Pardini, C. Scagnolari, E. Garaci, E.M. Coccia, Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists, Expert Opin. Biol. Ther. 15:S59-S70, 2015.
17 Zee J. Heating the patient: a promising approach. Ann Oncol 13(8):1173-1184, 2002.   DOI
18 Schwartz LH, Litie' re S, de Vries E, et al: RECIST 1.1: Update and clarification-From the RECIST committee. Eur J Cancer 62:132-137, 2016   DOI
19 Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, et al. Inhibition of HIF-1 by PX-478 enhances the anti-tumor effect of gemcitabineby inducing immunogenic cell death in pancreatic ductal ade-nocarcinoma. Oncotarget. 6(4):2250-2262, 2015.   DOI
20 Renia M, Bonettoa E, Cordio S, Passoni P, Carlo Milandri C, Cereda S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a Phase III randomized trial. Pancreatology. 6(5):454-463, 2006.   DOI
21 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69:7-34, 2019.   DOI
22 Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49:358-366, 2017.   DOI
23 Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY and Kim YS: Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact. 233:25-34, 2015.   DOI
24 Crawford HC, Pasca di Magliano M, Banerjee S. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Gastroenterology. 156:2073-2084, 2019.   DOI
25 United States National Cancer Institute. Pancreatic cancer: statistics. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics, 2018.